V Mware Acquisition
Total Consideration
$86.29B
Share price: $142.50
Purchase-Price Allocation
Goodwill
$54.21B
Intangibles
$45.57B
Assets Acquired
$110.92B
Liabilities Assumed
$31.27B
Pro-Forma Combined Entity
Revenue
$52.19B
Net Income
+$6.47B
8 years of history · ending 2025-11-02 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 17.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 0.00% | -1.10% | -4.60% | -3.60% | -0.80% | 0.20% |
| Foreign Rate Differential | -0.80% | -16.30% | -52.50% | -48.60% | -22.80% | -19.10% |
| Other Adjustments | — | — | — | — | — | — |
| R&D Tax Credits | 0.00% | 2.90% | 7.60% | 4.30% | 2.30% | 1.40% |
| Effective Tax Rate | 1.90% | -1.78% | -22.90% | -21.20% | 0.40% | 7.50% |
Cash vs Accrual
| Item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $35.0M | −$8.08B | −$510.0M | −$518.0M | $29.0M | $939.0M |
| Income Taxes Paid (Cash) | $349.0M | $512.0M | $741.0M | $501.0M | $775.0M | $908.0M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$86.29B
Share price: $142.50
Purchase-Price Allocation
Goodwill
$54.21B
Intangibles
$45.57B
Assets Acquired
$110.92B
Liabilities Assumed
$31.27B
Pro-Forma Combined Entity
Revenue
$52.19B
Net Income
+$6.47B
Purchase-Price Allocation
Goodwill
$14.0M
Intangibles
$570.0M
Assets Acquired
$600.0M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-11-02
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Employee Severance | Employee Severance | +$428M | — | $76M |
| Other Restructuring | Other | +$169M | — | — |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).